For active B12 deficiency, most clinicians recommend weekly or biweekly shots for the first 4 to 6 weeks, then a maintenance shot every 1 to 3 months
No human safety data : The complete absence of human clinical trials means the safety profile, side effects, optimal dosing, and pharmacokinetics in humans are entirely unknown Animal-to-human translation is uncertain : Metabolic differences between mice and humans mean that the magnitude of effects (e.g., weight loss, grip strength improvement) may not translate
Seniors may be predisposed to vitamin B12 deficiency, especially if they suffer from health conditions
However, complete discontinuation typically results in weight regain, making CagriSema a long-term commitment requiring indefinite maintenance dosing
When used for intermittent medication administration, because there is a small volume associated with the device called the dead space, the initial dose must include a larger volume to account for the volume in the dead space after the first dose is administered